2020 ASCO Virtual Direct™ Highlights
W

2020 ASCO Update on Resected Stage III BRAF V600-mutant Melanoma: Is Dabrafenib + Trametinib an Effective Adjuvant Therapy Following Surgery With an Excellent Safety Profile?

By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
32 views
July 17, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
05:37
Melanoma Bridge 2023

COLUMBUS 7-Year Update: Encorafenib + Binimetinib vs. Vemurafenib or…

Feat. R. Dummer
52:19
Winship Melanoma and Cutaneous Oncology Symposium

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Feat. S. Patel
20:55
2023 West Oncology Conference

2023 West Oncology Conference: Melanoma Updates

Feat. M. Mooradian
04:45
Sapna Patel

Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…

20:32
Melanoma Bridge 2023

Targeted Therapy in BRAF-Mutated Metastatic Melanoma

Feat. R. Dummer
13:31
Melanoma Bridge 2023

What Is the Best Initial Treatment for Unresectable Mucosal Melanoma…

Feat. J. Luke
17:32
Insights from 2023 Society for Melanoma Research Annual Meeting

2023 SMR Congress Insights: "DREAMseq Trial Final 2-year OS Dat…

Feat. M. Atkins
24:22
Total Health

2022 Sedona Melanoma Updates From ASCO: Overview and Treatment

Feat. K. Lewis
21:38
Penn Medicine Abramson Cancer Center

Updates in Systemic Therapy for Melanoma

Feat. T. Mitchell
13:20
Penn Medicine Abramson Cancer Center

Penn Medicine Updates in Oncology 2023: Melanoma

Feat. J. Cohen
10:39
Moffitt Cancer Center

Clinical Implications of COMBI-d and COMBI-v Trials on OS in Patient…

Feat. A. Tarhini
27:29
Total Health

2023 ASCO® Direct Philadelphia: Melanoma Updates

Feat. M. Orloff
13:55
Northwestern Medicine Oncology and Hematology

Utilization of COMBI-APlus Data in Clinical Practice: Adapted Pyrexi…

Feat. S. Chandra
07:53
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "aTezolizumab, bevAcizumab, and Cobimetinib…

Feat. E. Burton
12:09
Omid Hamid

Evolving Management of Melanoma CNS Metastases and the Impact of COM…

25:21
Melanoma 2023: 33rd Annual Cutaneous Malignancy Update

Treatment of Advanced Melanoma in 2023

Feat. K. Bollin
15:38
Melanoma Bridge 2023

New Interesting Targets From Recent Melanoma Research

Feat. O. Hamid
39:11
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Fred Hutchinson Cancer Center Updates on Melanoma and Other Skin Can…

Feat. S. Bhatia